Transcriptomic analysis of one patient with lupus skin lesions treated with anifrolumab
- 13 August 2024
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (4)
Abstract
No abstract availableFunding Information
- Société Française de Dermatologie et de Pathologie Sexuellement Transmissible
- Pfizer
- AstraZeneca France
This publication has 8 references indexed in Scilit:
- Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosusJournal of the American Academy of Dermatology, 2023
- Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled TrialArthritis & Rheumatology, 2022
- Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus ErythematosusNew England Journal of Medicine, 2022
- Trial of Anifrolumab in Active Systemic Lupus ErythematosusNew England Journal of Medicine, 2020
- Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappaAnnals of the Rheumatic Diseases, 2018
- Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine Type I Interferon LoopJournal of Investigative Dermatology, 2017
- Identification of type I interferon‐associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approachesExperimental Dermatology, 2007
- Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupusProceedings of the National Academy of Sciences, 2003